Fanzhi Medicine has recently announced the successful completion of a D+ round financing amounting to hundreds of millions of yuan, with the participation of several prestigious investment institutions. This funding round aims to further embed AI technology within the realm of rapid disease diagnosis, thereby accelerating the advancement and global expansion of intelligent diagnostic products. Since its inception in 2016, Fanzhi Medicine has specialized in genetic testing and precision diagnosis, developing a suite of intelligent testing devices and reagent kits that are widely utilized in rapid testing applications. Furthermore, the company has established a leading domestic medical ecosystem platform, "Fanzhi Cloud Chain," which spans multiple domains of biomedicine. The company's founder disclosed that the proceeds will primarily be allocated towards the integration and innovation of AI and diagnostic products, the clinical translation of intelligent equipment, and the enhancement of global development efforts.